期刊
BRITISH JOURNAL OF CANCER
卷 99, 期 2, 页码 275-282出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6604461
关键词
colorectal; dose; irinotecan; response; toxicity; UGT1A1*28
类别
The aim of the study was to investigate the associations between UGT1A1*28 genotype and (1) response rates, (2) febrile neutropenia and ( 3) dose intensity in patients with metastatic colorectal cancer treated with irinotecan. UGT1A1*28 genotype was determined in 218 patients receiving irinotecan (either first-line therapy with capecitabine or second-line as monotherapy) for metastatic colorectal cancer. TA(7) homozygotes receiving irinotecan combination therapy had a higher incidence of febrile neutropenia (18.2%) compared to the other genotypes (TA(6)/TA(6) : 1.5%; TA(6)/TA(7) : 6.5%, P = 0.031). TA(7) heterozygotes receiving irinotecan monotherapy also suffered more febrile neutropenia (19.4%) compared to TA(6)/TA(6) genotype (2.2%; P = 0.015). Response rates among genotypes were not different for both regimens: combination regimen, P = 0.537; single-agent, P = 0.595. TA(7) homozygotes did not receive a lower median irinotecan dose, number of cycles (P-values >= 0.25) or more frequent dose reductions compared to the other genotypes (P-values for trend; combination therapy: 0.62 and single-agent: 0.45). Reductions were mainly (> 80%) owing to grade >= 3 diarrhoea, not (febrile) neutropenia. TA(7)/TA(7) patients have a higher incidence of febrile neutropenia upon irinotecan treatment, but were able to receive similar dose and number of cycles compared to other genotypes. Response rates were not significantly different.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据